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OBJECTIVE—Diabetes is associated with an increased risk of
death in women. Oxidative stress due to chronic hyperglycemia
leads to the generation of reactive oxygen species and loss of
chromosomal integrity. To clarify whether diabetes is a prema-
ture aging syndrome, we determined telomere erosion dynamics
and occurrence of structural chromosomal aberrations in women
of the Ludwigshafen Risk and Cardiovascular Health (LURIC)
Study.
RESEARCH DESIGN AND METHODS—Telomere lengths
and karyotypes were examined in peripheral blood mononuclear
cells. Regarding these parameters, surviving and deceased type 2
diabetic women of the LURIC study were compared with nondi-
abetic LURIC women with or without coronary heart disease and
with healthy female control subjects.
RESULTS—Signiﬁcantly enhanced telomere attrition was seen
in all LURIC subjects compared with healthy control subjects.
Although the average telomere-length loss is equivalent to well
10 years of healthy aging, telomere erosion was not associated
with outcome within the LURIC cohort. However, strikingly high
numbers of stable chromosomal aberrations were found in type
2 diabetic women but not in LURIC disease control subjects or in
healthy individuals. Furthermore, within the younger age-
groups, deceased type 2 diabetes patients had signiﬁcantly more
marker chromosomes than the surviving type 2 diabetic patients.
CONCLUSIONS—All women at high risk for cardiovascular
death have accelerated telomere erosion, not caused by type 2
diabetes per se but likely linked to other risk factors, including
dyslipidemia. By contrast, the occurrence of marker chromo-
somes is associated with type 2 diabetes and is a novel risk factor
for type 2 diabetes–related early death. Diabetes 57:2950–
2957, 2008
T
ype 2 diabetes is characterized by increased
morbidity and all-cause mortality (1,2). The com-
bination of excess caloric intake and reduced
physical activity leading to obesity, dyslipidemia,
and hypertension increases the risk for diabetes and
coronary heart disease (CHD). Recent data show that
among diabetic men, the mortality rate has decreased
signiﬁcantly, whereas in diabetic women, no such trend
was found (3). The all-cause mortality rate difference
between diabetic and nondiabetic women is considerable.
Therefore, the combination of diabetes with multiple risk
factors identiﬁes women at particularly high risk (2,4).
The relative risk for morbidity and mortality in women
with diabetes is increased compared with nondiabetic
control subjects (2,5). Diabetes may therefore be regarded
as a premature aging syndrome in which the overall
metabolic shift leads to genotoxic stress that results in
loss of chromosomal integrity (rev. in 6). Oxidative stress
plays a crucial role in the pathogenesis of type 2 diabetes
and in diabetes-associated complications. The generation
of reactive oxygen species (ROS) is a common down-
stream mechanism whereby multiple by-products of glu-
cose and (pro)inﬂammatory molecules exert adverse
effects (7–11). DNA damage and telomere attrition can
serve as markers of these processes and, consequently,
mirror the pace of biological aging (rev. in 12–14).
Hypothesizing along these lines, we studied telomere
erosion dynamics and/or the occurrence of structural
chromosomal aberrations in women with type 2 diabetes
who were participants of the Ludwigshafen Risk and
Cardiovascular Health (LURIC) prospective cohort study
(15). Life expectancy within the LURIC female cohort falls
short by 10 years compared with the general female
population in Germany.
Telomeric erosion was much further advanced in all
LURIC women, irrespective of type 2 diabetes, compared
with age-matched control subjects, the difference amount-
ing to 10 life-years. We further found a strikingly en-
hanced number of structural chromosomal aberrations in
the peripheral lymphocytes of women with type 2 diabetes
that was diabetes speciﬁc and, within the younger age-
groups, associated with mortality.
RESEARCH DESIGN AND METHODS
The LURIC study is an ongoing prospective cohort study investigating risk
factors for cardiovascular death in Caucasian individuals (15). Between June
1997 and January 2000, 3,266 individuals (2,266 men and 1,002 women) who
had undergone coronary angiography were included. All LURIC participants
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2950 DIABETES, VOL. 57, NOVEMBER 2008had elective coronary angiography and left ventriculography. CHD was
assessed by angiography using the maximum luminal narrowing estimated by
visual analysis. Clinically relevant CHD was deﬁned as the occurrence of at
least one stenosis 20% in at least 1 of 15 coronary segments. Individuals with
stenosis 20% were considered as control subjects (16). The institutional
review board at the A ¨rztekammer Rheinland-Pfalz approved the study. In-
formed written consent was obtained from each participant. All participants
were proﬁled in detail with regard to established risk factors for cardiovas-
cular disease. The cohort is followed for morbidity and mortality. Information
on vital status was obtained from local registries. No patient was lost to
follow-up. Death certiﬁcates were obtained in 97% of dead participants. Two
modes of death were classiﬁed: cardiovascular death and others. Cardiovas-
cular death included the following categories: sudden death, fatal myocardial
infarction, death due to congestive heart failure, death immediately after
intervention to treat CHD, fatal stroke, and other causes of death due to CHD.
Other modes of death covered all kinds of noncardiovascular deaths; those
succumbing to this mode of death were censored.
Because the chance to ﬁnd a novel risk factor in diabetes mortality
appeared more promising locking into a high-risk cohort, the present analysis
is restricted to women (Fig. 1). Among the 1,002 women who entered the
LURIC study, 204 had type 2 diabetes, and 798 had no signs of diabetes at the
time of enrollment. Median time of follow-up was 5.45 years. Up to the ﬁxed
day (20 January 2000), of the 204 type 2 diabetes subjects, 72 had died
(referred to as L-T2DMdec) and 132 had survived (referred to as L-T2DMsur).
From the nondiabetic subgroup 129 died, and 669 were still alive. Clinical data
of these patients are described in detail in Table 1.
The study combines a cross-sectional analysis and a follow-up approach.
From the L-T2DMdec and L-T2DMsur, 63 matching pairs were found on the
basis of CHD status, presence versus absence of dyslipidemia and/or hyper-
tension, and age. To test the impact of type 2 diabetes against this high-risk
proﬁle, two LURIC control groups were drawn from the surviving nondiabetic
patients. Of those, 23 and 20 matched with individuals of the type 2 diabetes
cohort for presence of dyslipidemia and age, respectively, solely differing in
the presence versus absence of angiographically proven CHD. These LURIC
control cohorts are in the following referred to as L-ctr.surCHD
 and
L-ctr.surCHD
, respectively (Fig. 1).
As fundamental healthy control subjects, we included and reexamined the
large cohort of normal women published by Perner et al. (17) and Mayer et al.
(18), comprising newborns to centenarians. To our knowledge and to their
own account, these individuals were healthy. The analysis of healthy control
subjects had been done using the same probes and the same microscope and
software. Blood samples from the LURIC cohort were drawn at baseline
between 1997 and 2000. Blood samples from the control subjects were drawn
between 1997 and 2002.
Clinical chemistry. Standard laboratory procedures were used as described
previously (15). Speciﬁcally, diabetes was diagnosed if 2 h after the oral
glucose load, plasma glucose was 1.25 g/l in the fasting state or 2 g/l,
respectively, or if individuals were receiving oral antidiabetics or insulin.
Aliquots of the 0-h sample were taken for determination of total serum
cholesterol and HDL and LDL fractions. A1C (normal range 3.4–6.1%) was
measured for all patients using an immunoassay (hemoglobin A1c UNIMATE
5; Hoffmann-LaRoche, Grenzach-Whylen, Germany).
Cell culture and metaphase preparation. Peripheral blood mononuclear
cells were isolated on density gradients (Lymphoprep; Nycomed Pharma,
Oslo, Norway) and washed in RPMI-1640 (Life Technologies, Paisley, U.K.)
twice before use. Peripheral lymphocytes were cultured and phytohemagglu-
tinin stimulated as described previously to obtain metaphase cells (17).
Fifteen metaphases from each individual were karyotyped according to
standard criteria (19) and analyzed under an Axioscope microscope (Zeiss,
Jena, Germany) equipped with a charged-coupled device camera, linked to the
Isis and telomere software (MetaSystems, Altlussheim, Germany). Abnormal
chromosomes were detected and further characterized by inverted gray scales
using the software.
Peptide nucleic acid probes and ﬂuorescence in situ hybridization. The
peptide nucleic acid (PNA) probe for telomeric sequences is a ready-to-use
probe included in the Telomere PNA FISH Kit/Cy3 (Dako, Glostrup, Den-
mark). The PNA centromeric probe for chromosome 2 was generated by Dako
and is available on request. The hybridization was performed according to the
manufacturer’s instructions and as detailed by Perner et al. (17). Reliability
and reproducibility of the telomere/centromere ﬂuorescence in situ hybrid-
ization (T/C-FISH) method had been tested by Perner et al. (17). The examiner
of the T/C-FISH and cytogenetic analyses (see below) was blinded to the
clinical status of the subjects analyzed.
Cytogenetic analysis. Stable chromosomal aberrations (translocations, in-
sertions, interstitial deletions, and inversions) are easily detectable while
performing T/C-FISH and were further characterized by inverted gray scales
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FIG. 1. Participants and selection criteria. T2DM, type 2 diabetes.
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DIABETES, VOL. 57, NOVEMBER 2008 2951of the original DAPI counterstaining. The frequencies of marker chromosomes
were quantiﬁed in all metaphases within each age-group (15 metaphases per
person) and expressed in percent. The same procedure was done with healthy
control subjects.
Statistical analysis of T/C data. Normalized data were derived by calculat-
ing the ratio of absolute telomere intensities and the centromeric reference
signal intensities of each chromosome 2 (T/C value). For each individual, 15
metaphases were analyzed. The primary data were compiled using the
telomere software program, and telomere intensities of the p- and q-arms of
each chromosome were obtained. From each patient, 1,300 single values
were analyzed, resulting in an individual median. These individual medians
were then used for further statistical analysis, which was performed with
SPSS 11.0 and SAS 9.1 for Windows. Individually matched samples were
compared using the Wilcoxon’s signed-rank test (metric and ordinal variables)
and conditional logistic regression to adjust for covariates. The Kruskal-Wallis
and the Mann-Whitney U test were used for nonmatched comparisons.
Survival distributions were drawn by means of the Kaplan-Meier method and
compared using the log-rank test. Regression curves were generated using
linear regression or with generalized linear models. Two-sided P values are
given; the criterion for statistical signiﬁcance was P  0.05. The sample size
for the two additional LURIC control groups, L-ctr.sur CHD
 and L-ctr.sur-
CHD
, in relation to the type 2 diabetes LURIC cohort (i.e., L-T2DMdec plus
L-T2DMsur) was planned based on estimated means and SDs of telomere
lengths in the LURIC cohort and the healthy control group. Here, normal
distribution of the data was assumed.
RESULTS
Telomere-length analysis. Metaphase chromosomes
from mononuclear cells taken at the baseline examination
of the type 2 diabetes cohort were subjected to T/C-FISH
telomere-length assessment and compared with age-
matched healthy control subjects. Figure 2A gives an
example of telomeric signals in a single metaphase, Fig. 2B
shows the same metaphase in inverted gray scales for
karyotyping, and Fig. 2C gives the resulting karyogram.
Telomere length was signiﬁcantly shorter in the entire type
2 diabetes cohort (P  0.0001) compared with healthy
control subjects (see telomere lengths of healthy control
subjects in Fig. 3A and telomere lengths of all LURIC
subgroups in Fig. 3B). Focusing on outcome, a difference
in telomere length between the L-T2DMsur and the
L-T2DMdec subjects was not demonstrated using condi-
tional logistic regression (Fig. 3B, black and white dots)
(P  0.104 without adjustment and 0.070 after adjustment
for C-reactive protein and the number of marker chromo-
somes). Overall, the loss in telomere length in type 2
diabetic patients corresponded to a remarkable telomere
attrition of 1 kb corresponding to 10 years compared
with normal age-matched control subjects (Fig. 3B). This
number is compatible with the reduced life expectancy of
all female LURIC patients. Figure 4 shows the mortality
curves of LURIC type 2 diabetic patients, LURIC patients
without type 2 diabetes, and for comparison, the mortality
curve of the general female population in Germany as
issued by the Statistische Bundesamt (20). To verify these
results, two further nondiabetic LURIC control groups
were deﬁned for comparison with the type 2 diabetes
cohort, L-ctr.surCHD
 and L-ctr.surCHD
 (Fig. 1). The
sample sizes were estimated based on the observed aver-
age telomere lengths and SDs of the type 2 diabetes cohort
TABLE 1
List of epidemiological, clinical, and biochemical parameters of the female LURIC participants on whom this study is based
Parameter
Type 2
diabetes,
survivors
Type 2
diabetes,
deceased
CAD, no
diabetes,
survivors
No CAD, no
diabetes,
survivors
P values
(Kruskal-Walis/
ANOVA)
n 63 63 20 23
Age (years) 65.74  8.94 66.33  8.99 68.33  8.21 65.97  7.97 Matching criteria
Type 2 diabetes* 63 (100) 63 (100) 0 (0) 0 (0) Selection criteria
Diabetes diet 63 (100) 63 (100) 0 (0) 0 (0)
Death 0 (0) 63 (100) 0 (0) 0 (0) Selection criteria
Active smoker 8 (12.7) 10 (15.9) 2 (10) 3 (13)
Hypertension† 63 (100) 63 (100) 12 (60) 23 (100) Selection criterion
BMI (kg/m²) 27.26  4.15 26.85  4.38 27.31  4.24 28.63  4.90 0.42122
CHD 43 (68.3) 50 (79.4) 0 (0) 23 (100) Selection criterion
MI 14 (22.2) 31 (49.2) 0 (0) 14 (60.8)
Stroke 5 (7.9) 7 (11.1) 1 (5) 1 (4.3)
Dyslipidemia‡ 63 (100) 63 (100) 20 (95) 23 (100) Selection criterion
A1C (%) 6.43  1.03 6.70  1.70 5.74  0.60 5.63  0.53 0.02320
OAD 6 (9.5) 9 (14.3) 0 (0) 0 (0) Selection criterion
Insulin treatment 4 (6.3) 10 (15.9) 0 (0) 0 (0) Selection criterion
Creatinine (mol/l) 82  20 89  57 69  8.8 72  11 0.00020
Creatinine clearance
(Cockroft-Gault formula) 81.54  24.81 77.83  29.22 79.03  17.17 83.41  25.31 0.59448
Creatinine clearance
(MDRD-short formula) 78.22  17.84 76.51  22.20 79.98  12.09 77.22  14.58 0.93046
Clearance below 60 ml/min 5 (7.9) 10 (15.9) 1 (5) 3 (13)
Total cholesterol (mg/dl) 209.27  45.63 206.90  46.05 244.30  57.65 224.54  48.62 0.01976
Triglycerides (mg/dl) 165.78  78.42 182.48  132.40 170.95  115.87 151.42  46.02 0.90922
Fibrinogen (mg/dl) 407.43  116.5 442.67  114.57 379.7  113.56 351.46  63.15 0.00007
Interleukin-6 15.96  8.84 14.21  14.21 ND ND
hsCRP 10.75  23.08 12.37  23.79 7.44  15.54 3.84  4.39 0.00763
Data are means  SD or n (%) of patients. *Diabetes was deﬁned according to World Health Organization/American Diabetes Association
criteria; in all probands without known history of diabetes, diabetes was ruled out by an oral glucose tolerance test. †Hypertension deﬁned
by the use of antihypertensive drugs and/or systolic blood pressure 140 and/or diastolic blood pressure 90 mmHg. ‡Dyslipidemia deﬁned
by use of lipoid lowering drugs and/or HDL 35 mg/dl, triglycerides 170 mg/dl, and total cholesterol 240 mg/dl. CAD, angiographically
proven coronary artery disease; MI, myocardial infarction; ND, not done; OAD, oral antidiabetic drug.
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7.5). Under conservative assumption of a difference be-
tween means of 7 and a common SD of 10, the power of
the comparison is 80% for a control group of a size n 
20. Although L-ctr.surCHD
 (n  20) and L-ctr.surCHD

(n  23) showed mean T/C values of 16.3  6 and 17.4,
respectively, which are lower than the mean value in type
2 diabetes (18.4  9.1), the differences were not statisti-
cally signiﬁcant (P  0.57 and 0.94, respectively) (Fig. 3B,
red and blue dots). Thus, all LURIC women had acceler-
ated telomere erosion and reduced life expectancy irre-
spective of type 2 diabetes and/or CHD.
Chromosomal aberrations. The T/C-FISH technique fur-
ther allows structural chromosomal aberrations to be
identiﬁed. The results are based on the number of marker
chromosomes (Fig. 2, asterisk) per metaphase, where the
proband is the statistical unit. Although the prevalence of
marker chromosomes was negligible in newborns and low
in the age-matched healthy control subjects, the number of
marker chromosomes found in L-T2DMdec and
L-T2DMsur was signiﬁcantly increased (P  0.0001) and
even exceeded that in the advanced-age healthy control
subcohort (Fig. 5A).
Speciﬁcally, we veriﬁed the statistically signiﬁcant dif-
ference between the type 2 diabetes cohort and healthy
control subjects by comparing type 2 diabetes with L-
ctr.surCHD
 and L-ctr.surCHD
. Although in type 2 dia-
betes, a mean frequency of 12.45% per metaphase was
observed, the corresponding values in the 50–80 years
subgroup of healthy control subjects were 1.75% (n  20),
FIG. 2. A representative metaphase and the corresponding karyogram. A: Metaphase hybridized with PNA probes and counterstained with DAPI.
Blue, DAPI; red, FISH with telomere- and chromosome 2-speciﬁc probes. B: The corresponding gray scale image (black and white) reveals the
chromosome bands that allowed marker chromosomes to be identiﬁed (*). C: Corresponding karyogram with the following karyotype: 49,
XX,2,4mar. (Please see http://dx.doi.org/10.2337/db08-0274 for a high-quality digital representation of this image.)
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 (n  20), and 2.5% in L-ctr.sur-
CHD
 (n  23). No differences could be shown between
the three control groups (P  0.3 in each pairwise com-
parison); however, each of the control groups differed
from type 2 diabetes (P  0.0001 in each comparison).
Therefore, the high frequency of marker chromosomes
can be attributed to type 2 diabetes.
Regarding survival, the number of stable chromosomal
aberrations was higher in L-T2DMdec when compared
with L-T2DMsur (P  0.09) (Figs. 5 and 6). Regression
analysis (Fig. 5B) yielded an age-dependent increase in the
number of marker chromosomes in L-T2DMsur (y 
2.7543x  0.1629; r
2  0.8326). However, in L-T2DMdec,
only a weak association with age was found (y  1.17x 
9.7086; r
2  0.4208). In Fig. 6, the corresponding regres-
sion curves ﬁtting the proportion of marker chromosomes
per person are given together with 95% CIs for the curves
(Fig. 6). They were determined using a generalized linear
model with log link function and negative binomial distri-
bution. For L-T2DMsur but not for L-T2DMdec, an associ-
ation with age was found (P  0.042 and 0.65, respectively)
(Fig. 5B). Furthermore, Fig. 5B suggests a difference in the
proportion of marker chromosomes between L-T2DMdec
and L-T2DMsur and a rising risk of dying with increase in
marker chromosomes for the younger women. Therefore,
the 63 case-control pairs (which were all matched for age
in yearly intervals) were split into two groups: those
younger than the median age (being 69 years) and those
older. In the younger group (32 pairs) L-T2DMdec had, in
median, one marker chromosome more than the matched
L-T2DMsur (P  0.034, Wilcoxon’s signed-rank test),
whereas in the older group (31 pairs), no such difference
was found (P  0.86).
DISCUSSION
In LURIC women, pan-genomic telomere length was sig-
niﬁcantly shorter compared with healthy control subjects.
The accelerated telomere attrition amounts to well 10
years of healthy aging (6,12,18). Although telomere length
was not associated with outcome within this cohort, the
cohort itself, however, has an increased risk of death,
reducing life expectancy by 10 years compared with the
general female population in Germany (Fig. 4). This study
was designed to ﬁnd chromosomal abnormalities associ-
ated with diabetes-related mortality. We intentionally re-
stricted our analysis to women, who are known to carry
the greater burden (21,22). Obviously, our core ﬁnding that
stable marker chromosomes in peripheral lymphocytes
are associated with an elevated risk of diabetes-related
death in younger women will have to be reevaluated in a
similar male setting to gain information on the overall
power of this novel risk factor. Our data are in line with
recent studies showing that enhanced telomere attrition is
associated with atherosclerosis (23,24). Accelerated telo-
mere erosion was found in diabetic patients (25–27). This
is conﬁrmed here; however, as evidenced by our disease
control subjects, acceleration of telomere attrition is inde-
pendent of type 2 diabetes. Alternatively, our data strongly
suggest that accelerated erosion is caused by dyslipidemia
(hypercholesterolemia and hypertriglyceridemia), a state
that is frequently associated with type 2 diabetes.
Dyslipidemia leads to an increased production of alde-
hydes, including methylglyoxal. A direct role for methylg-
lyoxal in telomeric attrition has not been observed so far.
However, methylglyoxal induces an increase of free radi-
cals (ROS) (28), and ROS might, albeit indirectly, acceler-
ate telomere attrition (29). Furthermore, methylglyoxal
causes stable modiﬁcation of DNA bases, which in turn
induces chromosomal aberrations, sister chromatid ex-
changes, and micronuclei in human lymphocytes treated
in vitro (30). Although there is an enzymatic defense
against methylglyoxal-induced DNA mutation, e.g., the
enzymes glyoxalase I and aldehyde reductase (31), both
enzymes are highly dependent on the concentration of
glutathione, which is severely reduced in diabetes (32).
Hence, it is conceivable that methylglyoxal-induced chro-
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FIG. 3. Telomere shortening between healthy control subjects and the
LURIC cohort. Telomere shortening of control subjects (h-ctr) (A) and
the LURIC cohort (B) is shown by their individual medians (dots) and
resulting regression curves. The x-axis gives the age of the donor, and the
y-axis gives the T/C ratios of ﬂuorescence intensities on the left and the
scale of kilobase pairs (kb) on the right. T2DM, type 2 diabetes.
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patients.
The rate of chromosome aberrations in human periph-
eral lymphocytes of healthy individuals has been known to
increase with advancing age (rev. in 33), possibly caused
by the permanent attack of ROS (14,34), diminished DNA
repair (35), altered DNA repair mechanisms (36), and
modiﬁed T-cell repertoire (37).
The most important ﬁnding of our study is the high load
of stable chromosomal aberrations in type 2 diabetes.
These stable chromosomal aberrations in type 2 diabetic
women outnumbered by far the marker chromosomes in
our control populations, i.e., healthy control subjects and
both LURIC control subgroups, and can be regarded as
dramatic also against the background of published data
(Fig. 5A). Tawn and Cartmell (38) found a prevalence of
0.66% of stable aberrations in healthy control subjects
aged 28–50 years. Kleinerman et al. (39) found a frequency
of 0.41 (6 months of age), 0.56 (age range 6–7 years), and
0.68% (age range 18–68 years) in three independent con-
trol groups. Likewise, Bender et al. (40) reported a fre-
quency of 0.65% in a cohort of 18- to 68-year-old
individuals. These prevalence rates compare well with the
rates of marker chromosomes in our healthy control
subjects.
The similar proportion of marker chromosomes in the
age-groups of deceased individuals suggests the presence
of a threshold (15%) that when reached, heralds death
within the mean follow-up time, i.e., 5 years.
At present, a conceptional gap exists between the
biomarker “load of marker chromosomes in lymphocytes”
and the mechanism of death in type 2 diabetic patients. It
is even unclear whether lymphocytes are in this aspect
representative of somatic cells or of other tissues or cell
systems with their well-known differences in cellular turn-
over rates. Theoretically, the key players in CHD, i.e.,
blood monocytes, lymphocytes, endothelial cells, vascular
ﬁbroblasts, and smooth muscle cells, while engaged in the
injury and repair struggle eventually giving rise to fatal
plaque formation and rupture (41), might acquire fatal
dysfunctions caused by diabetes-induced DNA damage.
There is a wealth of detailed data on diabetes-related
malfunctioning of these cells and platelets and on oxida-
tive stress on endothelial cells in atherosclerosis (42). In
addition, chromosomal alterations have been found in
atherosclerotic plaques (43). Further research aiming at a
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FIG. 4. Proportion of survivors of LURIC patients with (n  204) and without (n  798) type 2 diabetes according to Kaplan-Meier. The x-axis
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malfunction is warranted in the light of our ﬁnding that the
load of chromosomal markers in lymphocytes of diabetic
women is a senescence marker prognosticating premature
death.
In summary, the current study provides the largest
dataset currently available to address the relationship
between stable chromosomal aberrations and telomere
length and an association with survival outcome in women
affected by type 2 diabetes. We show that telomere short-
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2956 DIABETES, VOL. 57, NOVEMBER 2008ening is associated with classical cardiovascular disease
risk factors other than type 2 diabetes, whereas, in
younger women, the occurrence of chromosomal aberra-
tions is associated with type 2 diabetes and directly
correlated with the risk of death. Our observation that
most women with an increased load of marker chromo-
somes died during the observation period suggests the
presence of a threshold value (6). This assumption might
be supported by the fact that the state-of-the-art polyphar-
macy used to treat the LURIC cohort did not alter the
survival outcome (15).
In conclusion, future prospective studies in high-risk
populations should take into account telomere dynamics
and stable chromosomal alterations as global biomarkers
for outcome.
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